A-Ying Ma

A-Ying Ma

Auto-generated profile, based on publicly available information

A-Ying Ma

Zhongshan Hospital 1 Liver Cancer Institute Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education Shanghai, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
AMAying Ma
Aying Ma
JZJieyun Zou
Jieyun Zou
HZHui Zou
Hui Zou
LYLi Yuan
Li Yuan
RZRuihua Zhong
Ruihua Zhong
CGChao Gao
Chao Gao
Progesterone plays a crucial and indispensable role in regulating immunity and attenuating inflammation. Nestorone ® (NES, segesterone acetate) is a steroidal progestin and a 19-norprogesterone derivative with no -CH3 group radical at the 6-position. Here, we showed that NES enhanced the viability of lipopolysaccharide (LPS)-stimulated THP-1 cell-derived macrophages, potently inhibiting both arms of the Toll-like receptor 4 (TLR-4) signaling cascade triggered by LPS, especially the TLR-4/MyD88/NF-κB pathway. In addition, NES exerted an anti-inflammatory effect by significantly decreasing the secretion of inflammatory cytokines and chemokines in type II alveolar epithelial A549 cells and THP-1 cell-derived macrophages stimulated by LPS. Furthermore, we evaluated the potential of pre-treatment with NES 2 hours before LPS treatment to rescue the lung from acute LPS-induced injury, using an LPS-induced acute lung injury (ALI) mouse model. In this study NES alleviated lung inflammation and damage through reducing leukocyte infiltration and inflammatory cytokines in mouse bronchoalveolar lavage fluid (BALF) and lung tissues. Interestingly, we found that NES at 1 mg/kg was superior to 0.1 or 10 mg/kg or to dexamethasone (DEX, 5 mg/kg) in prolonging survival in mice experiencing lethal LPS-induced injury, decreasing acute lung inflammation, and alleviating diffuse alveolar damage in the lungs of C57 mice. Overall, our study suggested that concentration was one of the key factors in determining the anti-inflammatory potency of NES, and therefore NES may serve as a promising novel therapeutic agent to treat pulmonary inflammatory diseases such as ALI/acute respiratory distress syndrome (ARDS) by modulating TLR-4 signaling.

2 September 2026 in Molecular Cancer Research
Verified
Journal Article
Open access
SLShi-Lin Lin
Shi-Lin Lin
YWYue Wang
Yue Wang
YZYi-Min Zheng
Yi-Min Zheng
AKAi-Wu Ke
Ai-Wu Ke
AMA-Ying Ma
A-Ying Ma
CGChao Gao
Chao Gao
Metabolic plasticity driven by mitochondrial oxidative phosphorylation (OXPHOS) is increasingly recognized as a key determinant of therapeutic tolerance in hepatocellular carcinoma (HCC), but the upstream regulators that preserve electron transport chain stability during treatment remain poorly defined. In this study, we identified paraoxonase 1 (PON1) as a clinically relevant regulator of mitochondrial metabolism and lenvatinib response in HCC. PON1 was markedly upregulated in HCC and independently associated with poor overall and recurrence-free survival. Functionally, PON1 promoted tumor growth and conferred robust tolerance to lenvatinib. Mechanistically, PON1 directly interacted with and stabilized NDUFA4, a key component required for complex IV assembly, thereby maintaining mitochondrial membrane potential, complex IV integrity, and OXPHOS-dependent adenosine triphosphate production while limiting reactive oxygen species accumulation. Genetic silencing of PON1 or NDUFA4 impaired mitochondrial respiration, increased oxidative stress, and restored lenvatinib sensitivity in HCC cells and xenograft models. Structure-guided virtual screening identified the Food and Drug Administration–approved CFTR corrector lumacaftor as a potent modulator of PON1 that disrupted the PON1–NDUFA4 interaction and enhanced the antitumor efficacy of lenvatinib in vivo. These findings identify the PON1–NDUFA4 axis as a previously unrecognized metabolic vulnerability that sustains mitochondrial respiratory fitness and lenvatinib resistance in HCC. Targeting mitochondrial protein-stabilizing mechanisms such as PON1–NDUFA4 may offer a broadly applicable strategy for overcoming therapy resistance in liver cancer and other aggressive malignancies. Implications: These findings establish mitochondrial protein stabilization as an actionable therapeutic vulnerability and provide a rationale for combination strategies to overcome targeted therapy resistance in HCC.